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V8 Balloon
(n=20)
MHI Cohort
(n=20) P-Value
Age (Years), Mean(SD) 83.1  7.5 85.5  6.8 0.31
Male, (%) 13 (65.0) 14 (70.0) 0.74
STS Score (%), Mean(SD) 9.8  7.0 11.5  9.8 0.64
LVEF (%), Mean(SD) 44.9  18.3 41.9  19.5 0.62
Maximum Balloon Diameter (mm),
Mean(SD)
26.1  1.5 24.2  1.1 <0.001
Baseline AVA (cm2), Mean(SD) 0.77  0.22 0.78  0.22 0.95
Post AVA (cm2), Mean(SD) 1.07  0.34 0.94  0.24 0.17
Change AVA (cm2), Mean(SD) 0.30  0.23 0.17  0.21 0.063
Change in AI (Class improvement)
3 class deterioration, (%)
0 (0) 1 (6.3) 0.45
2 class deterioration, (%)
0 (0) 0 (0)
1 class deterioration, (%)
6 (30.0) 3 (18.8)
No change, (%)
13 (65.0) 9 (56.3)
1 class improvement, (%)
1 (5.0) 2 (12.5)
2 class improvement, (%)
0 (0) 1 (6.3)
New AVCD*, (%) 0 (0) 0 (0) ———
Temporary Pacemaker*, (%) 1 (5.0) 1 (5.0) 1.00
New PPM*, (%) 0 (0) 0 (0) ———
MAE*, (%) 0 (0) 1 (5.0) 1.00
Abbreviations: STS ¼ Society of Thoracic Surgeons; LVEF ¼ left ventricular ejection fraction;
AVA ¼ aortic valve area; AI ¼ aortic insufﬁciency; AVCD ¼ atrioventricular conduction disorder;
PPM ¼ permanent pacemaker; MAE ¼major adverse event (deﬁned as mortality, emergency
surgery, or stroke).
* Fisher's exact test used to assess statistical signiﬁcance.
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Background: The aim of this study is to assess the utility of transesophageal echo-
cardiography (TEE)-guided procedure on clinical outcomes in pts with severe aortic
stenosis undergoing transcatheter aortic valve implantation (TAVI).
Methods: Between January 2008 and February 2012, 418 pts with symptomatic
severe aortic stenosis underwent TAVI at 18 sites and were enrolled in the Brazilian
multicenter registry. We assessed outcomes of pts who underwent TAVI using peri-
procedural TEE (TEE; n¼ 295) vs. with no TEE-guided procedure (noTEE; n¼123).
Stepwise Cox multivariable regression analysis were performed to assess the associ-
ation between the TTE-guided procedure and long-term mortality.
Results: Pts treated with TEE vs. noTEE tended to be younger (81.208.87 vs.
82.247.33 years, p¼0.21), with higher rates of diabetes, hyperlipidemia, hyperten-
sion, history of angina, and more likely to receive Sapien than CoreValve (18.6% vs.
2.4%; 81.4% vs. 97.6%; p<0.001, respectively). Compared with pts with noTEE,
those with TEE had lower STS risk score (13.3211.48% vs. 16.1611.40%;
p¼0.02), but similar EUROScore (19.702143% vs. 21.4315.55%; p¼0.24).
TEE-guided procedure was associated with a signiﬁcant reduction in 5-year all-cause
mortality (19.0% vs. 37.4%; p<0.001). By multivariable analysis, TEE (vs. noTEE)
was an independent predictor of freedom from death (HR 0.63; 95% CI [0.42 to 0.93];
p¼0.02).
Conclusions: In pts with severe aortic stenosis, TAVI guided by TEE was associated
with lower long-term mortality as compared to pts without TEE-guided procedure.
A randomized trial is required to determine the advantage of this approach.
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Background: Balloon (bal) aortic valvuloplasty (BAV) has reemerged with trans-
catheter valve therapy. Cylindrical bal have been the device of choice despite limi-
tations. The V8 (InterValve Inc.) bal with larger segments separated by a narrowed
waist is designed to permit enhanced ﬁxation and better leaﬂet opening without
annular compromise.
Methods: We report our experience using the V8 bal in 20 matched patients (pts)
receiving BAV compared to a subset of 20 pts from a 403 pt BAV database which
used cylindrical bals. Pts were propensity matched on a 1:1 basis on age, gender, left
ventricular ejection fraction (LVEF), and baseline aortic valve area (AVA). Endpoints
included change in AVA by echo, change in aortic insufﬁciency (AI), and new
atrioventricular conduction defect's (AVCD) by 24-hour ECG. The need for post-
procedure temporary pacemaker (TPM) or new permanent pacemaker (PPM) was
noted. Maximum bal diameter (dia) for each patient was recorded. Reported V8 dia
were of the larger aortic root segments of the bal hour glass bal. Major adverse events
(MAE) included procedure related death, emergency surgery or stroke.
Results: V8 and cylindrical bal groups were similar across age, sex, Society of
Thoracic Surgeons' risk score, LVEF, and baseline AVA. The change in AVA from
baseline to post-procedure trended towards being larger for V8 pts than cylindrical bal
pts (0.30cm2  0.23 vs. 0.17  0.21; p¼0.063) and max bal size was signiﬁcantly
larger for V8 pts enabled by the bal shape. There were no differences in outcomes of
TMP, PPM, AVCD, or MAE (Table 1).B240 JACC Vol 62/18/Suppl B j October 27–NovemberConclusions: Preliminary ﬁndings in this small experience suggest an advantage for
enhancing AVA when using the V8 bal compared to cylindrical bals. Additionally,
there was no evidence of increased AI class or occurrence of AVCD or MAE.
Findings from a multicenter registry will be available for presentation.
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Background: Valve thrombosis after surgical bioprosthetic aortic valve replacement
is uncommon. This has yet to be evaluated in the context of transcatheter aortic valve
implantation (TAVI).
Methods: Between January 2008 and February 2013, all consecutive patients who
underwent TAVI were analyzed in this multi-center registry (9 centers). Transcatheter
heart valve (THV) dysfunction was deﬁned as aortic valve area <1.2 cm2 and mean
aortic valve gradient 20 mmHg or peak velocity 3 m/s, or moderate or severe
prosthetic valve regurgitation. THV thrombosis was deﬁned as THV dysfunction
secondary to thrombosis, which was diagnosed based on the timing post-TAVI,
response to anticoagulation therapy, echo ﬁndings or histopathology.
Results: Probable valve thrombosiswas observed in 15 patients atmedian follow-up period
of 6months (IQR 4 to 10) after TAVI.Mean age was 80.1 years and 9 were male gender. In
majorityof cases (n¼12, 80%), theEdwardsTHVwas implanted.Themost commonclinical
presentation was dyspnea on exertion (n¼8) whereas 3 patients were asymptomatic. One
patient presented with acute heart failure and a non-ST elevation myocardial infarction.
Transvalvular gradient was found to bemarkedly elevated in all patients who presentedwith
exertional dyspnea. Thickened leaﬂets without visible thrombus were observed in 4 (23%)
patients, thrombotic apposition of leaﬂets or thrombotic mass on leaﬂets in the remaining 11
(77%) patients. In 8 (53%) patients, anticoagulation resulted in normalization of transaortic
gradient within 3months. In 4 (27%) patients, anticoagulationwas initiated and follow-up is
anticipated. Two (13%) patients underwent successful surgical aortic valve replacement,
while the remaining 1 (7%) died during the index hospitalization.
Conclusions: Although a rare phenomenon, THV thrombosis may occur within the
ﬁrst 2 years following TAVI and usually presents with dyspnea and an increased
gradient. It would appear that anticoagulation is very effective in normalizing the
gradient and should be considered even in patients without visible thrombus on echo.
These data suggest that further studies are required to evaluate the importance of
DAPT versus anticoagulation after TAVI.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
